title: Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.
abstract: High-affinity interleukin 2 receptors (IL-2Rs) are expressed by T cells activated in response to foreign histocompatibility antigens but not by normal resting T cells. To exploit this difference in IL-2R expression, anti-Tac-M, a murine monoclonal antibody specific for the IL-2R alpha chain, was used to inhibit organ allograft rejection. However, the use of murine anti-Tac as an immunosuppressive agent was limited by neutralization by human anti-murine antibodies and by weak recruitment of effector functions. To circumvent these difficulties, a humanized antibody to the IL-2R, anti-Tac-H, was prepared. This molecule is human with the exception of the hypervariable segments, which are retained from the mouse. In vivo survival of anti-Tac-H is 2.5-fold longer than simultaneously administered anti-Tac-M (terminal t1/2, 103 hr vs. 38 hr). In addition, anti-Tac-H is less immunogenic than anti-Tac-M when administered to cynomolgus monkeys undergoing heterotopic cardiac allografting. Specifically, all monkeys treated with anti-Tac-M developed measurable anti-anti-Tac-M levels by day 15 (mean onset, 11 days). In contrast, none of the animals receiving anti-Tac-H produced measurable antibodies to this monoclonal antibody before day 33. Finally, there was a prolongation of graft survival in the cynomolgus heterotopic cardiac allograft model in animals receiving anti-Tac. In animals that received anti-Tac-M, the allograft survival was prolonged compared to that of the control group (mean survival, 14 +/- 1.98 days compared to 9.2 +/- 0.48 days; P less than 0.025). Graft survival was further prolonged by anti-Tac-H with a mean survival of 20.0 +/- 0.55 days (compared to controls, P less than 0.001; compared to anti-Tac-M, P less than 0.02). There was no toxicity attributable to the administration of either form of anti-Tac. Thus, anti-Tac-H significantly prolonged allograft survival in primates, without toxic side effects, and may be of value as an adjunct to standard immunosuppressive therapy in humans.
authors.affiliation: Surgery Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
authors.forename: P S
authors.initials: PS
authors.lastname: Brown
authors.forename: G L
authors.initials: GL
authors.lastname: Parenteau
authors.forename: F M
authors.initials: FM
authors.lastname: Dirbas
authors.forename: R J
authors.initials: RJ
authors.lastname: Garsia
authors.forename: C K
authors.initials: CK
authors.lastname: Goldman
authors.forename: M A
authors.initials: MA
authors.lastname: Bukowski
authors.forename: R P
authors.initials: RP
authors.lastname: Junghans
authors.forename: C
authors.initials: C
authors.lastname: Queen
authors.forename: J
authors.initials: J
authors.lastname: Hakimi
authors.forename: W R
authors.initials: WR
authors.lastname: Benjamin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology*; D008252:Macaca fascicularis; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2